ÃâÒßѧ·ÖÐÍ,immunological classificationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »¹Ô­Ò¶ËáÔØÌå,reduced folate carrierÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ò½Ôº½¹ÂÇÒÖÓôÁ¿±í(HADS),Hospital Anxiety and Depression Scale(HADS)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« PML/RAR¦ÁÈںϻùÒò,PML/RAR¦Á fusion geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ëÄË鯬,Peptide fragmentsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½ð»ÆÉ«ÆÏÌÑÇò¾ú³¦¶¾ËØA,SEAÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« HoxA»ùÒò,HoxA geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ѪҺ¶ñÐÔÖ×Áö,hematological malignancyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« MHC¢ñÀà,MHC class¢ñÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈýôÇ»ù±½¼×Ëá¶þ¾ÛÌå,trihydroxybenzoic acid dimmerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« È˰×Ѫ²¡Ï¸°û,human leukemia cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸´ÔÓºËÐÍ,complex karyotypeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ESHAP·½°¸,ESHAP regimenÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼±ÐÔÁܰÍϸ°û°×Ѫ²¡Ç°ÆÚ,Preceding acute lymphoblastic leukemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿çϵ±í´ï,cross-lineage expressionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« MLL»ùÒòÖØÅÅ,MLL gene rearrangementÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÓÕÆ­RNA,Decoy RNAÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹ÇËè½þÈó,Bone marrow involvementÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÃÖÂþ´óBϸ°ûÐÔÁܰÍÁö,diffuse large B-cell lymphomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°ûÖÜÆÚµ°°×G,Cyclin GÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ѪҺϵͳ¶ñÐÔÖ×Áö,Hematological malignancesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Õý³£ºËÐÍ,Normal karyotypeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« DLBCL,Diffuse large B-cell lymphomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹ÇËèÖ×Áö,bone marrow neoplasmsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÑÜÉúȾɫÌå,derivative chromosomeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹ÇËèÇÖ·¸,Bone marrow involvementÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« È˹ÇËè»ùÖÊϸ°û,human bone marrow stromal cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« NOD-SCIDСÊó,NOD-SCID miceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶ùͯ¼±ÐÔ°×Ѫ²¡,Childhood leukemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÑÇÉéËá×¢ÉäÒº,arsenous acid injectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹ÇËèÖ×Áö/¼Ì·¢ÐÔ,bone marrow neoplasms/secondaryÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« TEL-AML1ÈںϻùÒò,TEL-AML1 fusion geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿Ë¡ÐÔÔöÖ³,clonal expansionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÁªºÏ»¯Ñ§ÖÎÁÆ,Combined chemotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼ä±ä´óϸ°ûÁܰÍÁö,anaplastic large cell lymphomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÁÜϵ·Ö»¯¿¹Ô­,Lymphoid differentiation antigenÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸ÆÔØÌå,Calcium ionophoreÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °×ϸ°ûÖ±·½Í¼,WBC histogramÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼±ÐÔËèϵϸ°û°×Ѫ²¡,acute myeloid leukemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÂýÐÔÁ£Ï¸°û,chronic myeloidÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« K562/DNRϸ°û,K562/DNR cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ָͻ״Ê÷ͻϸ°ûÈâÁö,Interdigitating dendritic cell sarcomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ά¼×Ëá/ÖÎÁÆÓ¦ÓÃ,tretinoin/therapeutic useÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« GPI궨µ°°×,GPI-linked proteinsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« DNA½»Áª,DNA crosslinksÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×Ô·¢»º½â,Spontaneous remissionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »º½âºóÖÎÁÆ,Postremission therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·Ö×Ó±íÐÍ,Molecular phenotypeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×ÔȻɱÉË(NK)ϸ°û,natural killer cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÁܰÍϵͳ¶ñÐÔÖ×Áö,Lymphoid malignanciesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼±ÐÔÁܰͰ×Ѫ²¡,acute lymphatic leukaemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ô­·¢ÐÔ½áÍâÁܰÍÁö,Primary extranodal LymphomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ÇºÎ½Ü½ðÊÏÁܰÍÁö,non-Hodgkin's lymphomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼±ÐÔÁܰÍϸ°ûÐÔ°×Ѫ²¡,acute lymphoblastic leukemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« CD7,human CD7Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÃÖÂþ´óBϸ°ûÐÍÁܰÍÁö,diffuse large B-cell lymphomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« JMϸ°û,JM cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« KG1aϸ°û,KG1a cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÓÐË¿·ÖÁÑ×èÖÍ,Mitotic arrestÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÃÖÂþÐÔ´óBϸ°ûÐÔÁܰÍÁö,Diffuse Large B-cell lymphomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶à·¢ÐÔ¹ÇËèÁö(MM),multiple myeloma(MM)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶àÔ­·¢Ö×Áö,Multiple primary tumorsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« È¥¼×»ù»¯ÖÎÁÆ,demethylation therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« R-CHOP·½°¸,R-CHOP regimenÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ѪÇåÓÎÀëÇáÁ´,serum free light chainsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶à·¢ÐÔ¹ÇËèÁö/Õï¶Ï,Multiple myeloma/diagnosisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Kasumi-1ϸ°ûÖê,Kasumi-1 cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °×Ѫ²¡Ïà¹ØÃâÒß±íÐÍ,leukemia-associated immunophenotypeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÖÜÆÚµ°°×ÒÀÀµÐÔ¼¤Ã¸2,Cyclin Dependent Kinase2(CDK2)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« Pgenesil-1ÔØÌå,Pgenesil-1 vectorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶þÏ©±û»ù¶þÁòÃÑ,diallyl disulfideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶þÏ©±û»ùÈýÁòÃÑ,diallyl trisulfideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´ÅÐÔÄÉÃ×,Magnetic NanoparticlesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« תÌúµ°°×ÊÜÌå2,transferrin receptor 2Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« MnSODÄ£Ä⻯ºÏÎï,Mimics of MnSODÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« MAPKÐźÅתµ¼,MAPK signal transductionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´óBϸ°ûÁܰÍÁö,large B-cell lymphomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« HL-60°×Ѫ²¡Ï¸°û,HL-60 leukemic cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÌåÄÚÍâ,in vivo and in vitroÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« U266ϸ°ûϵ,U266 cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ȾɫÌå²»Îȶ¨ÐÔ(CIN),chromosome instability(CIN)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ²æÍ·¿òµ°°×O1,FOXO1 proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« δÕÛµüµ°°×·´Ó¦,unfolded protein responseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶Ì·¢¼ÐRNA¸ÉÈÅ,short hairpin RNA interferenceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´ß»¯Ñǵ¥Î»,catalytic subunitÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÔöÇ¿×Ó½áºÏµ°°×,enhancer binding proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×éµ°°×È¥¼×»ù»¯,histone demethylationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« caveolin-1µ°°×,caveolin-1 proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö¬ÖÊÌå°¢Ã¹ËØ,pegylated liposomal doxorubicinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿¹°×Ѫ²¡×÷ÓÃ,Anti-leukemia effectÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÐÛ»ÆÎ¢ÉúÎïÌáȡҺ,Realgar bioleaching solutionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÁܰÍĸϸ°ûÐÔÁܰÍÁö,Lymphoblastic cell lymphomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« SGC7901/ADRϸ°û,SGC7901/ADR cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Aurora¼¤Ã¸ÒÖÖÆ¼Á,Aurora kinase inhibitorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶à·¢ÐÔ¹ÇËèÁö/²¡Àíѧ,Multiple myeloma/patholÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µ°°×øÌåÒÖÖÆ¼ÁMG-132,proteasome inhibitor MG-132Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿¹Ö×ÁöÁªºÏ»¯ÁÆ·½°¸/ÖÎÁÆÓ¦ÓÃ,antineoplastic combined chemotherapy protocols/therapeutic useÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °×Ѫ²¡K562ϸ°û,K562 cells of leukemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈܹÇÐÔ²¡±ä,osteolytic bone lesionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« T-VAD·½°¸,T-VAD regimenÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«